

- Vasculitic neuropathy, 2700
- Vasculitis. *See also* Vasculitis syndromes
 anemia and, 630f
 as cause of fever of unknown origin, 137t, 141
 CNS
 clinical features of, 2192
 dementia in, 2607
 differential diagnosis of, 2192, 2568
 imaging in, 386e-4f, 386e-6f, 441e-19f, 2192f
 definition of, 2179
 diagnosis of, 2181
 differential diagnosis of, 2181, 2181t
 drug-induced, 382, 2193, 2218t
 in familial Mediterranean fever, 2214
 leukocytoclastic (cutaneous small-vessel), 25e-11f, 76e-15f, 133t, 135, 364t, 368
 necrotizing. *See* Necrotizing vasculitis
 of nerve and muscle, 619
 paraneoplastic, 614t, 619
 in relapsing polychondritis, 2204
 rheumatoid, 2138
 secondary, 2179t, 2193
 in serum sickness, 2193
 in serum sickness–like reactions, 2193
 single-organ, 2191
 in Sjögren's syndrome, 2167, 2167t
 skin manifestations of, 76e-15f, 364t, 366
 treatment of, 2181–2182
 urticarial, 132t, 135
- Vasculitis syndromes, **2179**
 approach to the patient, 2181–2182, 2181f
 Behçet's syndrome. *See* Behçet's syndrome
 classification of, 2179, 2179t
 Cogan's syndrome. *See* Cogan's syndrome
 cryoglobulinemic. *See* Cryoglobulinemia
 cutaneous, 386e-6f
 definition of, 2179
 diagnosis of, 386e-1, 386e-1–6f, 2181, 2181f
 differential diagnosis of, 2181, 2181t
 diseases associated with, 2193
 eosinophilic granulomatosis with polyangiitis.
 See Eosinophilic granulomatosis with
 polyangiitis (Churg-Strauss syndrome)
 giant cell arteritis. *See* Giant cell arteritis
 (temporal arteritis)
 granulomatosis with polyangiitis. *See*
 Granulomatosis with polyangiitis
 (Wegener's)
 idiopathic cutaneous, 2191–2192
 IgA vasculitis. *See* IgA vasculitis (Henoch-
 Schönlein)
 Kawasaki disease. *See* Kawasaki disease
 microscopic polyangiitis. *See* Microscopic
 polyangiitis
 pathogenesis of, 2179–2181, 2180t
 polyangiitis overlap syndromes, 2193
 polyarteritis nodosa. *See* Polyarteritis nodosa
 polymyalgia rheumatica. *See* Polymyalgia
 rheumatica
 primary CNS, 386e-4f, 386e-6f, 2192, 2192f
 Takayasu's arteritis. *See* Takayasu's arteritis
 treatment of, 2181–2182, 2181f, 2182t
 vessel damage in, 2179–2180
- Vasculogenesis, 102e-14
- Vasculopathy. *See specific types*
- Vasoactive intestinal peptide (VIP)
 actions of, 570
 ectopic production of, 609t
 in prolactin secretion, 401e-2
 reference values for, 2764t
 regulation of, 2090
 in swallowing, 255
- Vasoactive intestinal peptidoma (VIPoma).
 See VIPoma (vasoactive intestinal
 peptidoma)
- Vasoconstriction, 725
 cold-induced, 478e-1
 cyanosis in, 249
 heat conservation by, 124
 localized hypoxia and, 248
- Vasodilation, 725
 as adaptation to hypoxia, 248
 endothelium-dependent, 1615
 in exercising muscle, 265e-8
 heat loss by, 124
- Vasodilators
 circulating, in shock, 1746
 for heart failure, 1509, 1509f
 for hypertension, 1624t, 1625
- Vasodilator testing, 1657
- Vasogenic edema, 1777
- Vasointestinal polypeptide, 330
- Vasomotor rhinitis, 2122
- Vasopressin. *See also* Arginine vasopressin (AVP)
 action of, 332e-5f, 332e-6f
 in coordination of emesis, 103e-25
 deficiency, 2259t
 ectopic production of. *See* Syndrome of
 inappropriate antidiuretic hormone
 (SIADH)
 in shock, 1745
- Vasopressin antagonists. *See* Vaptans
 (vasopressin antagonists)
- Vasospasm, after subarachnoid hemorrhage,
 1785, 1787
- Vasovagal syncope. *See* Syncope, neurally
 mediated
- Vaughan-Williams classification, of antiarrhythmic
 drugs, 273e-5, 273e-6t
- VCAM-1 (vascular cell adhesion molecule-1),
 89e-1, 1242, 2150
- Vd (volume of distribution), 34, 935
- VDR (vitamin D receptor), 2464–2465
- VDRL (Venereal Disease Research Laboratory)
 test, 1137, 1137f, 1259
- Vedolizumab, 1962
- Vegetarian diet, 300, 626, 644
- Vegetations, valvular, 76e-12f, 816, 816f
- Vegetative state, 1771
- VEGF. *See* Vascular endothelial growth factor
 (VEGF)
- Veins. *See* Blood vessels
- VeIP regimen, for testicular cancer, 591
- “Velcro” crackles, 2161
- Vellus hair, 331
- Velocardiofacial (DiGeorge) syndrome, 83e-6,
 375e-1, 465e-2, 2113, 2483
- Vemurafenib
 action and targets of, 41, 101e-8, 102e-5t,
 103e-16f, 103e-17t, 103e-19
 adverse effects of, 103e-17t
 for hairy cell leukemia, 135e-2
 for lung cancer, 521
 for melanoma, 102e-5t, 103e-17t, 103e-19,
 498, 499
 relapse following treatment with, 32
 resistance to, 103e-23
- Venereal Disease Research Laboratory (VDRL)
 test, 1137, 1137f, 1259
- Venezuelan equine encephalitis virus, 1306t, 1317
- Venlafaxine
 adverse effects of, 7e-6, 2640t, 2682t, 2710t,
 2716–2717
 for anxiety disorders, 2711
 for cataplexy, 190
 for depression, 64, 2672, 2710t, 2716
 for hot flushes with androgen deprivation
 therapy, 7e-6
 for menopausal symptoms, 2383
 for migraine prevention, 2594t
 for neuropathic pain, 94–95, 2682t
 for pain, 91t, 94, 2672
 for panic disorder, 2709
 pharmacology of, 2716
 for PTSD, 2712
- Venomous snakebite. *See* Snakebites
- Venoocclusive disease, of liver. *See* Sinusoidal
 obstructive syndrome
- Venoocclusive disease with immunodeficiency
 (VODI) syndrome (Sp110 deficiency),
 375e-2, 2110
- Venous disorders, of extremities
 anatomic considerations, 1650
 chronic venous disease. *See* Chronic venous
 disease
 venous thrombosis. *See* Venous
 thromboembolism (VTE)
- Venous hum, 51e-6
- Venous hypertension, 357, 367
- Venous lake, 364t, 367
- Venous malformation, 364t, 367
- Venous O₂ concentration, 1748t
- Venous pressure, 253
- Venous return, 51e-7
- Venous sinus thrombosis, 2566
- Venous thoracic outlet syndrome, 122
- Venous thromboembolism (VTE), 277, **743**.
 See also Deep vein thrombosis (DVT);
 Pulmonary embolism (PE)
 in antiphospholipid syndrome, 2135, 2135t
 vs. arterial thrombosis, 744–745
 with brain tumor, 598
 in burn patient, 166e-2
 coagulation cascade in, 743–744
 cyanosis in, 249
 edema in, 253
 epidemiology of, 743
 etiology of, 277t, 743–744, 743t
 genetic considerations in, 277t, 743t, 744
 history in, 404–405
 in HIV infection, 1262
 incidence of, 274, 740
 in liver disease, 739–740, 739f, 739t
 lupus anticoagulant in, 740
 mesenteric, 1979, 1980t
 oral contraceptives and, 2391, 2391t
 paraneoplastic, 612t, 613
 pathophysiology of, 1631–1632, 1631f
 postmenopausal hormone therapy and, 2383,
 2384t
 postthrombotic syndrome, 1631, 1631f,
 1634
 prevention of
 fondaparinux for, 753
 in hospitalized patients, 1636, 1637t
 in mechanically ventilated patient, 1743
 in surgical patient, 55
 prothrombotic states and, 1631
 renal, 1866
 risk factors for, 405t, 1631
 acquired, 277t, 743t, 744
 age, 405f
 history of thrombosis, 404–405
 inherited, 277t, 743t, 744
 suppurative intracranial, 783, 905–906, 905f
 Ventilation-perfusion mismatch/heterogeneity,
 306e-4, 306e-4f
 in asthma, 47e-2
 in cardiogenic pulmonary edema, 47e-5
 in COPD, 47e-2
 in hypoxia, 247–248
 in interstitial lung diseases, 1710
 in pulmonary hypertension, 1656
 in sepsis/septic shock, 1755
- Ventilation-perfusion scan, 1664
- Ventilator-associated pneumonia (VAP)
 A. *baumannii*, 1037
 in burn patient, 166e-2
 clinical features of, 810
 complications of, 812
 diagnosis of, 810–811, 811t, 915
 epidemiology of, 810
 etiology of, 809, 809t
 failure to improve, 812
 follow-up, 812
 MRSA, 811, 812
 P. *aeruginosa*, 811, 812, 1044
 pathophysiology of, 810, 810t, 915, 1743
 prevention of, 12e-2, 12e-3, 813, 914–915,
 914t
 prognosis of, 812–813
 risk factors for, 914
 S. *maltophilia*, 1048
 treatment of, 811–812, 812t
- Ventilatory function
 adequacy of, 306e-3
 disturbances of. *See* Hyperventilation;
 Hypoventilation; Respiratory disorders
 flow-related properties of, 306e-1–2, 306e-2f,
 306e-3f
 measurement of, 306e-6